Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Zhangang Xiao is active.

Publication


Featured researches published by Zhangang Xiao.


Cancer Research | 2014

A small-molecule modulator of the tumor-suppressor miR34a inhibits the growth of hepatocellular carcinoma.

Zhangang Xiao; Chi Han Li; Stephen L. Chan; Feiyue Xu; Lu Feng; Yan Wang; Jian Dong Jiang; Joseph J.Y. Sung; Christopher H.K. Cheng; Yangchao Chen

Small molecules that restore the expression of growth-inhibitory microRNAs (miRNA) downregulated in tumors may have potential as anticancer agents. miR34a functions as a tumor suppressor and is downregulated or silenced commonly in a variety of human cancers, including hepatocellular carcinoma (HCC). In this study, we used an HCC cell-based miR34a luciferase reporter system to screen for miR34a modulators that could exert anticancer activity. One compound identified as a lead candidate, termed Rubone, was identified through its ability to specifically upregulate miR34a in HCC cells. Rubone activated miR34a expression in HCC cells with wild-type or mutated p53 but not in cells with p53 deletions. Notably, Rubone lacked growth-inhibitory effects on nontumorigenic human hepatocytes. In a mouse xenograft model of HCC, Rubone dramatically inhibited tumor growth, exhibiting stronger anti-HCC activity than sorafenib both in vitro and in vivo. Mechanistic investigations showed that Rubone decreased expression of cyclin D1, Bcl-2, and other miR34a target genes and that it enhanced the occupancy of p53 on the miR34a promoter. Taken together, our results offer a preclinical proof of concept for Rubone as a lead candidate for further investigation as a new class of HCC therapeutic based on restoration of miR34a tumor-suppressor function.


Tumor Biology | 2014

A potential antitumor ellagitannin, davidiin, inhibited hepatocellular tumor growth by targeting EZH2

Yan Wang; Jing-Yi Ma; Sheung Ching Chow; Chi Han Li; Zhangang Xiao; Ru Feng; Jie Fu; Yangchao Chen

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and is the third most common cause of cancer-related deaths. Currently available treatment options for HCC patients are scarce resulting in an urgent need to develop a novel effective cure. Polygonum capitatum is a medicinal herb which has been used to treat inflammatory diseases in Miao nationality of China. We recently isolated a pure compound davidiin from P. capitatum extract. Four HCC cell lines were treated with davidiin. Cell viability was recorded by MTT assay. siRNAs targeting enhancer of zeste homolog 2 (EZH2) were applied to modulate the expression of EZH2. Established xenograft mice models of HCC were applied to evaluate the in vivo anticancer activity of davidiin. We investigated the anticancer activity and the underlying mechanism of davidiin. The compound inhibited HCC cell growth and also suppressed tumor growth in xenografted HCC mouse. Such inhibition was facilitated by specifically downregulation on EZH2. The compound possesses anticancer activity both in vitro and in vivo which warrants further clinical investigation as a potential anti-HCC agent.


Journal of Cellular Physiology | 2015

Autophagy Mediates HBx-Induced Nuclear Factor-κB Activation and Release of IL-6, IL-8, and CXCL2 in Hepatocytes

Millore X.M. Luo; Matthew T. V. Chan; Le Yu; Sidney Yu; Feng Wu; Zhangang Xiao; Xiaojuan Wang; Lin Zhang; Alfred S.L. Cheng; Simon S.M. Ng; Francis K.L. Chan; Chi Hin Cho; Jun Yu; Joseph J.Y. Sung; William Ka Kei Wu

Hepatitis B virus (HBV) and one of its encoded proteins, HBV X protein (HBx), have been shown to induce autophagy in hepatoma cells. Substantial evidence indicates that autophagy is a potent suppressor of inflammation. However, sporadic reports suggest that autophagy could promote pro‐inflammatory cytokine expression and inflammation in some biological contexts. Here, we show that overexpression of HBx induces LC3B‐positive autophagosome formation, increases autophagic flux and enhances the expression of ATG5, ATG7, and LC3B‐II in normal hepatocytes. Abrogation of autophagy by small interfering RNA against ATG5 and ATG7 prevents HBx‐induced formation of autophagosomes. Autophagy inhibition also abrogates HBx‐induced activation of nuclear factor‐κB (NF‐κB) and production of interleukin‐6 (IL‐6), IL‐8, and CXCL2. These findings suggest that autophagy is required for HBx‐induced NF‐κB activation and pro‐inflammatory cytokine production and could shed new light on the complex role of autophagy in the modulation of inflammation. J. Cell. Physiol. 230: 2382–2389, 2015.


International Journal of Cancer | 2017

EZH2 coupled with HOTAIR to silence MicroRNA-34a by the induction of heterochromatin formation in human pancreatic ductal adenocarcinoma.

Chi‐Han Li; Zhangang Xiao; Joanna Hung Man Tong; Ka Fai To; Xiangdong Fang; Alfred Sl Cheng; Yangchao Chen

MicroRNA‐34a (miR‐34a) is frequently downregulated in pancreatic ductal adenocarcinoma (PDAC) cells, however, the silencing mechanism remains unclear. Enhancer of zeste homolog 2 (EZH2) is overexpressed in PDAC, and our previous miRNA profiling showed that inhibition of EZH2 in PDAC cells led to the re‐expression of a group of tumor suppressor miRNAs including miR‐34a. Here, we studied the effect of ectopic EZH2 expression to the silencing of miR‐34a, and identified HOTAIR as an interacting partner to induce heterochromatin formation during miR‐34a repression. We identified EZH2 as a major player in silencing miR‐34a. Inhibition of EZH2 upregulated miR‐34a expression in PDAC cells, while EZH2 overexpression in human pancreatic ductal epithelial (HPDE) cells repressed miR‐34a expression and decreased the miR‐34a promoter activity. We then showed that HOTAIR played a critical role in EZH2‐mediated repression of miR‐34a, as knockdown of HOTAIR attenuated the miR‐34a inhibition effect in EZH2‐overexpressing HPDE cells. HOTAIR physically interacted with miR‐34a promoter, and the EZH2‐interacting region located at 5′ HOTAIR RNA was essential in repressing miR‐34a and promoting cell proliferation. More importantly, we showed that the interaction between EZH2 and HOTAIR underlay the silencing of miR‐34a through induction of heterochromatin formation. We first showed that manipulation of EZH2 level interfered the occupancy of heterochromatin markers H3K9me2, heterochromatin associated protein 1α and 1γ in PDAC cells. In turn, we showed that knockdown of HOTAIR reduced the occupancy of EZH2 at miR‐34a promoter. The identification of HOTAIR‐guided miR‐34a silencing opened a new avenue in miR‐34a‐oriented therapy against PDAC.


European Journal of Pharmacology | 2014

Role of microRNA-95 in the anticancer activity of Brucein D in hepatocellular carcinoma

Zhangang Xiao; Sheung Ching Chow; Chi Han Li; Shing Chun Tang; Stephen Kwok-Wing Tsui; Zhi-Xiu Lin; Yangchao Chen

Brucea javanica fruit has been used to treat amebic dysentery, malaria and various parasites and it has been applied as an anti-cancer agent in Traditional Chinese Medicine. Brucein D (BD) is a naturally occurring compound extracted from Brucea javanica fruit which shows anti-cancer activity against pancreatic cancer. Here, we further demonstrated that BD inhibited hepatocellular carcinoma (HCC) cell growth in vitro and tumor growth in vivo that were attributed to the induction of cell apoptosis. BD did not exert growth inhibition on non-tumorigenic human hepatocytes. MTT assay was used to measure cell viability. Annexin V and TUNEL assay were applied to identify apoptotic cells in cell suspension and in tissue section respectively. Downstream micro-RNA (miRNA) targets of BD were screened out by miRNA array. miRNAs and their target proteins were identified by bioinformatics analysis and luciferase reporter assay. 39 miRNAs regulated by BD in HCC were identified. miR-95 was found to be a potential drug target of BD. We further identified CUG triplet repeat RNA-binding protein 2 (CUGBP2) as the downstream target of miR-95. Our data suggested that BD exerted its anti-cancer activity against HCC through modulation of miR-95 expression.


Critical Care | 2016

The involvement of regulatory non-coding RNAs in sepsis: a systematic review

Jeffery Ho; Hung Chan; Maggie Haitian Wang; Jun Yu; Zhangang Xiao; Xiaodong Liu; Gordon Choi; Czarina C.H. Leung; Wai T. Wong; Zheng Li; Tony Gin; Matthew T. V. Chan; William Ka Kei Wu

BackgroundSepsis coincides with altered gene expression in different tissues. Accumulating evidence has suggested that microRNAs, long non-coding RNAs, and circular RNAs are important molecules involved in the crosstalk with various pathways pertinent to innate immunity, mitochondrial functions, and apoptosis.MethodsWe searched articles indexed in PubMed (MEDLINE), EMBASE and Europe PubMed Central databases using the Medical Subject Heading (MeSH) or Title/Abstract words (“microRNA”, “long non-coding RNA”, “circular RNA”, “sepsis” and/or “septic shock”) from inception to Sep 2016. Studies investigating the role of host-derived microRNA, long non-coding RNA, and circular RNA in the pathogenesis of and as biomarkers or therapeutics in sepsis were included. Data were extracted in terms of the role of non-coding RNAs in pathogenesis, and their applicability for use as biomarkers or therapeutics in sepsis. Two independent researchers assessed the quality of studies using a modified guideline from the Systematic Review Center for Laboratory animal Experimentation (SYRCLE), a tool based on the Cochrane Collaboration Risk of Bias tool.ResultsObservational studies revealed dysregulation of non-coding RNAs in septic patients. Experimental studies confirmed their crosstalk with JNK/NF-κB and other cellular pathways pertinent to innate immunity, mitochondrial function, and apoptosis. Of the included studies, the SYRCLE scores ranged from 3 to 7 (average score of 4.55). This suggests a moderate risk of bias. Of the 10 articles investigating non-coding RNAs as biomarkers, none of them included a validation cohort. Selective reporting of sensitivity, specificity, and receiver operating curve was common.ConclusionsAlthough non-coding RNAs appear to be good candidates as biomarkers and therapeutics for sepsis, their differential expression across tissues complicated the process. Further investigation on organ-specific delivery of these regulatory molecules may be useful.


OncoImmunology | 2016

Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer

Zhenyu Xu; Jing Shen; Maggie Haitian Wang; Tao Yi; Yangyang Yu; Yinxin Zhu; Bo Chen; Jianping Chen; Longfei Li; Minxing Li; Jian Zuo; Hui Jiang; Dexi Zhou; Jiajie Luan; Zhangang Xiao

ABSTRACT The B7 gene family has crucial roles in the regulation of adaptive cellular immunity. In cancer, deregulation of co-inhibitory B7 molecules is associated with reduced antitumor immunity and cancer immune evasion. FDA approval of cancer immunotherapy antibodies against cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death-1 (PD-1)—both ligands of the B7 family—demonstrate the impact of these checkpoint regulators in cancer. Using data from cBioPortal, we performed comprehensive molecular profiling of the 10 currently known B7 family proteins in 105 different cancers. B7 family members were amplified in breast cancer: with B7 mRNA levels upregulated in a cohort of 1,098 patients with all types of breast cancer and in 82 patients with triple-negative breast cancer. Promoter methylation analysis indicated an epigenetic basis for deregulation of certain B7 family genes in breast cancer. Moreover, patients with B7-H6 genomic alterations had significantly worse overall survival, and certain clinical attributes were associated with B7-H6 expression, which indicates that B7-H6 may be a potential target for breast cancer immunotherapy. Finally, using network analysis (based on data from cBioportal), we identified BTLA, MARCH8, PLSCR1 and SMAD3 as potentially involved in T cell signaling under regulation of B7 family proteins.


Oncology Letters | 2018

Therapeutic targeting of noncoding RNAs in hepatocellular carcinoma: Recent progress and future prospects (Review)

Zhangang Xiao; Jing Shen; Lin Zhang; Mingxing Li; Wei Hu; C. H. Cho

Due to the high mortality rate and unsatisfactory treatment options available, hepatocellular carcinoma (HCC) remains one of the most common malignancies and a leading cause of cancer-associated mortality. Novel therapeutic targets for HCC are urgently required. Advanced RNA sequencing technology enables the identification of considerable amounts of noncoding RNAs (ncRNAs), including small noncoding RNAs and long noncoding RNAs, which exhibit no protein-coding activities. In this respect, ncRNAs and their regulatory processes are important factors in liver tumorigenesis. The present review focuses on the characteristics and biological roles of ncRNAs in HCC. Potential therapeutic applications of ncRNAs in HCC are also evaluated.


Oxidative Medicine and Cellular Longevity | 2017

The Beneficial Effects of Quercetin, Curcumin, and Resveratrol in Obesity

Yueshui Zhao; Bo Chen; Jing Shen; Lin Wan; Yinxin Zhu; Tao Yi; Zhangang Xiao

Over the past two decades, obesity has been one of the major public health concerns in most countries. In the search for new molecules that could be used for the treatment of obesity, good perspectives have been opened up for polyphenols, a class of natural bioactive phytochemicals. Experimental and limited clinical trial evidence supports that some polyphenols such as quercetin, curcumin, and resveratrol have potential benefit functions on obesity treatment. This brief review focuses on the main functions of the above-named polyphenols on adipose tissue. These polyphenols may play beneficial effects on adipose tissue under obese condition by alleviating intracellular oxidative stress, reducing chronic low-grade inflammation, inhibiting adipogenesis and lipogenesis, and suppressing the differentiation of preadipocytes to mature adipocytes.


Life Sciences | 2017

1,25-Dihydroxyvitamin D3 suppresses gastric cancer cell growth through VDR- and mutant p53-mediated induction of p21

Mingxing Li; Longfei Li; Lin Zhang; Wei Hu; Jing Shen; Zhangang Xiao; Xu Wu; Franky L. Chan; Chi Hin Cho

Aims: Previous studies have indicated that vitamin D deficiency correlates with cancer risk and vitamin D potentiates antitumor effects in a variety of cancers. The antitumor effect of vitamin D on gastric cancer was rarely studied. We aimed to investigate the antitumor effect of vitamin D on gastric cancer and underlying mechanisms. Main methods: We investigated the antitumor activity of the active form of vitamin D, 1&agr;,25‐dihydroxyvitamin D3 (1,25(OH)2D3) on gastric cancer cells (TMK1) and immortalized normal gastric cells (HFE145) by using MTT, colony formation and Flow cytometry assays. We demonstrated the important role of vitamin D receptor (VDR) and mutant p53 (mutp53) in mediating the antitumor action of 1,25(OH)2D3 by using siRNA, western‐blot, immunofluorescent staining and immunoprecipitation assays. Key findings: 1,25(OH)2D3 could significantly inhibit proliferation and induce cell cycle arrest in TMK1 but not in HFE145. Furthermore, 1,25(OH)2D3 stimulated p21 expression and suppressed cyclin‐dependent kinase 2 (CDK2) expression in TMK1 in a VDR‐dependent manner. High levels of VDR in human gastric cancer tissues and cancer cell lines implicated that vitamin D could display more potent pharmacological action against malignant cells. Besides, mutp53 but not wild type p53 was essential for 1,25(OH)2D3‐stimulated upregulation of p21 in gastric cancer cells. Indeed, mutp53 could stabilize nuclear VDR level through interaction with VDR. Significance: Our results suggest that 1,25(OH)2D3 inhibits gastric cancer cell growth through VDR and mutp53 interaction followed by the modulation of p21/CDK2. We propose that vitamin D might be used for the prophylactic treatment for malignant diseases in the stomach.

Collaboration


Dive into the Zhangang Xiao's collaboration.

Top Co-Authors

Avatar

Jing Shen

The Chinese University of Hong Kong

View shared research outputs
Top Co-Authors

Avatar

Chi Hin Cho

The Chinese University of Hong Kong

View shared research outputs
Top Co-Authors

Avatar

Mingxing Li

The Chinese University of Hong Kong

View shared research outputs
Top Co-Authors

Avatar

Yangchao Chen

The Chinese University of Hong Kong

View shared research outputs
Top Co-Authors

Avatar

Lin Zhang

The Chinese University of Hong Kong

View shared research outputs
Top Co-Authors

Avatar

Tao Yi

Hong Kong Baptist University

View shared research outputs
Top Co-Authors

Avatar

Chi Han Li

The Chinese University of Hong Kong

View shared research outputs
Top Co-Authors

Avatar

Joseph J.Y. Sung

The Chinese University of Hong Kong

View shared research outputs
Top Co-Authors

Avatar

Jun Yu

The Chinese University of Hong Kong

View shared research outputs
Top Co-Authors

Avatar

Lin Zhu

Hong Kong Baptist University

View shared research outputs
Researchain Logo
Decentralizing Knowledge